EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage



Stipan Jonjic

Name of the laboratory

CapRi: Center for monoclonal antibody production
Center for Proteomics
Faculty of Medicine
University of Rijeka
B. Branchetta 20, 51 000 Rijeka, Croatia
+385 51 651 260 / 651 250

Members of the laboratory

Members: Center for Proteomics
Team Leader
Research Personnel
Tihana Lenac Rovis
Johanna Julia Reichel
Vanda Juranic Lisnic
PhD Students
Laboratory Engineers
Edvard Marinovic
Research administrative and management support

Laboratory activity

The Center for Proteomics, established in 2006 at the University of Rijeka Faculty of Medicine, is focused on high-throughput monoclonal antibodies (mAb) development for cutting-edge applications, including proteome analysis. It already disposes of a bank with several hundred hybridoma cell lines secreting mAbs to a large variety of target proteins. The Center has participated in more than thirty collaborative projects with prestigious research institutes, universities and biotech SMEs from SE Europe, EU and the USA.

These projects are mainly based on the production and characterization of mAbs for research purposes. In many instances the reagents generated at the Center have played a key role in various discoveries and resulted in joint publications in the leading journals.

Research activities

The Center's pilot project for the high-throughput production of mAbs was performed on the VZV (Varicella Zoster Virus) proteome. Ever since, the Center has been continuously working on new projects and services, which include:

  • generation of diverse sets of mAbs against murine and human cytomegalovirus (CMV) proteins (including mAbs against viral proteins expressed on the surface of infected cells (neutralising Ab capacity), structural and non-structural CMV proteins with an emphasis on viral proteins involved in immunoevasion functions and viral MHC I-like proteins for studies in structural biology);
  • generation of mAbs to other immunologically important targets (mAbs against viral chemokines and cytokines, mAbs to several proteins expressed on human NK cells, potential markers on pancreatic tumor, neuro-stem cells);
  • custom mAbs/hybridoma development;
  • development of novel immunotherapeutic approaches to treat viral infections based on fusion proteins consisting of anti-viral mAbs and soluble ligands for different lymphocyte receptors.

Techniques available

  • Protein immunogen expression and purification
  • Production of murine mAbs
  • mAb purification (HPLC, 5mg scale, adaptation to serum-free media)
  • mAb fragmentation
  • Ab characterization (western blot, immunoprecipitation, ELISA, flow cytometry, laser scanning, confocal microscopy, immunohistochemistry)
  • Mycoplasma testing

Publications (2016-present)

  • Arapović M, Brizić I, Popović B, Jurković S, Jordan S, Krmpotić A, Arapović A, Jonjić S: Intrinsic contribution of perforin to NK cell homeostasis during viral infection. Frontiers in Immunology, accepted for publication (2016)
  • Lenac Rovis T, Jonjic, S: Pregnancy-specific glycoprotein (PSG) expression in normal gastrointestinal tract and in tumours detected with novel monoclonal antibodies. mAbs, accepted for publication (2016)
  • Mndelboim O, Glasner A, Roth Z, Varvak A, Miletic A, Isaacson B, Bar-On Y, Jonjic S, Khalaila I: Identification of novel O glycosylations in the NK killer receptor Ncr1 essential for its activity, Cell Discovery, accepted for publication (2016) (IF: 12.413)